Consumers Beware of Counterfit and Potentially Harmful version of Alli

This week, the FDA is warning consumers about a counterfeit and potentially harmful version of Alli 60 mg capsules (120 count refill kit). Tests conducted by GlaxoSmithKline (GSK) found that the counterfeit version is lacking orlisat, the active ingredient in Alli. Additionally, the counterfeit contains sibutramine. Sibutramine is a drug that should not be taken without physician oversight and can harmfully conflict with other medications.

For more information and the FDA news release, please visit:

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm197857.htm